Table 2.
ILD Prevalence by PFT Indication
| PFT Indication | Indication Risk Categorya | Derivation Cohort (n = 1,271) |
External Validation Cohort (n = 384) |
Prospective Validation Cohort (n = 343) |
|---|---|---|---|---|
| Pulmonary disease | ||||
| Asthma | 0 | 3/61 (4.9) | 0/10 | 3/36 (8.3) |
| Bronchiectasis | 1 | 6/40 (15) | 0/1 | 0/0 |
| COPD/emphysema | 1 | 16/151 (10.6) | 2/42 (4.8) | 12/36 (33.3) |
| ILD | 3 | 97/114 (85.1) | 44/71 (62) | 3/3 (100) |
| Other ILD featuresb | 1 | 3/24 (12.5) | 0/9 | 3/6 (50) |
| Nodule(s) | 0 | 3/59 (5.1) | 4/38 (10.5) | 0/2 |
| Pulmonary hypertension | 2 | 7/24 (29.2) | 5/50 (10) | 3/18 (16.7) |
| Sarcoidosis | 2 | 12/37 (32.4) | 0/2 | 1/2 (50) |
| Other | 0 | 3/75 (4) | 2/12 (16.7) | 1/2 (50) |
| Cough and/or dyspnea | 1 | 28/272 (10.3) | 0/0 | 24/113 (21.2) |
| Cardiac disease | 0 | 5/79 (6.3) | 0/0 | 2/18 (11.1) |
| Rheumatologic disease | 3 | 8/17 (47.1) | 2/15 (13.3) | 6/10 (60) |
| Malignancy | 0 | 16/247 (6.5) | 8/108 (7.4) | 5/79 (6.3) |
| Other | 0 | 5/71 (7) | 1/12 (8.3) | 0/18 |
See Table 1 legend for expansion of abbreviation.
a
Assigned based on derivation cohort prevalence.
b
Restrictive lung disease, lung crackles, abnormal imaging, and hypoxemia.